This year I would like to start my address to you with a wish for good health, persistence and steady withstanding of our principles and in our attempts to defend the values we believe in.
In spite of the fact we live in times of transition and generation clashes, taking care of the health, both our own and that our our loved ones is still a priority of the society. This priority defines our dedication to our work, even though we face difficulties. The lack of political, economic and social stability on our main export markets predetermined to a certain extent our financial performance in 2015. We managed to maintain our position on the domestic market, but our total sales and EBITDA still decreased with 13.7%. This effect was expected, although of course not wished for.
Our success through out the year was mostly in our long-term strategic projects in the whole Group, including the sale of shares in our daughter company Extab, which we hope opens the doors for further work on the registration of our product Tabex on new markets with good outlooks. Our daughter company Sopharma Trading Ad established itself on the Serbian market and is now building partnerships and business with baby steps. There are many examples.
The year, which we enter now seemingly, will also offer lots of surprises. We believe we will face them in the most reasonable way and since we know by experience that an opportunity hides in every negative situation, we will try to use it.
Thank you for your trust.
Ognian Donev, PhD,
Chairman of the Board of Directors and Executive Director of Sopharma AD
SOPHARMA is one of the biggest and established manufactures of medicines in Bulgaria. The nomenclature of the Company exceeds 170 medications including almost all pharmacotherapeutic groups.
SOPHARMA is the only Bulgarian manufacturer of suppositories and solutions for injection for humane medicine. The Company is the owner of a significant number of patents and know-how for more than 300 technologies. Most valuable are the Company’s own original developments in the field of phytochemistry, used for preparation of pure medicinal substances and extracts of medicinal plants. Among them, the products Tribestan®, Nivalin®, Carsil®, Tabex® stand out for their high value and international recognition. A priority place in the investment policy is given to the development of manufacture, in compliance with the requirements for Good Manufacturing Practice.
SOPHARMA is a founder-member of the Association of Bulgarian Pharmaceutical Manufacturers; a member of the European Generic Association. The Company is a member also of the European organisation of manufacturers of medicines sold over the counter, the so-called OTC- products; a member of the European organization of small and medium-sized pharmaceutical companies. The main mission of SOPHARMA is to manufacture high-quality, accessible and efficient medicinal products that will guarantee the health and life of consumers.